Turn R&D Upside Down: When Product Development Pipelines Fail to Meet Aggressive Growth Targets, a Radical Transformation of R&D May Be Called For

By Canner, Niko; Mass, Nathaniel J. | Research-Technology Management, March-April 2005 | Go to article overview

Turn R&D Upside Down: When Product Development Pipelines Fail to Meet Aggressive Growth Targets, a Radical Transformation of R&D May Be Called For


Canner, Niko, Mass, Nathaniel J., Research-Technology Management


Is R&D a rewarding investment for the world's largest companies? The question, at first glance, seems merely rhetorical. After all, U.S. companies will have spent more than $180 billion in 2004 on R&D, according to National Science Foundation data.

But have these sizable investments resulted in a significant stream of breakthrough innovations? The evidence is not overwhelming. An in-depth study of successful and unsuccessful innovation over the previous 40 years at Exxon Chemical (now ExxonMobil Chemical) revealed that the company's substantial R&D activities produced only two major breakthroughs during that entire period. Rather than big new ideas and products, the company generated mostly smaller, lower-value process innovations.

But Exxon was not alone. The same study found that commercialized R&D across the entire chemical industry had been declining for some time (1).

The pharmaceutical industry, one of the most reliant on breakthrough R&D, has been experiencing a similar innovation drought, despite huge investments. Between 1996 and 2002, major pharmaceutical companies doubled their annual research spending, reaching $32 billion. Yet during this same period, the number of new drugs brought to the market plunged from 53 to 17. GlaxoSmithKline, the Number 2 player in the industry, introduced just three new products in 2003, only one of which it discovered.

Are we witnessing a crisis in corporate R&D? Although the paucity of genuine breakthroughs seems extraordinary, Exxon, GlaxoSmithKline, and other research-dependent giants have suffered from what appears to be a common vicious cycle in corporate R&D environments. Under pressure to deliver consistent, predictable revenue growth, these companies add more projects to the R&D pipeline to compensate for low success rates. Research becomes fragmented and relatively small-bore projects receive support in order to maintain a full portfolio of growth options. Before long, resources, talent and focus are spread thinly. Meanwhile, the pace of commercialization slows, leading to the erroneous conclusion that still more projects are needed.

The Problem of Portfolios

This dismal chain of events didn't happen by accident. It seems to be an inevitable result of the portfolio model, long advocated by many prominent product development experts, in which a large number of research projects are rigorously managed through a series of stages and approval gates.

While the portfolio model has brought some discipline to the often-undisciplined world of research, the approach has failed to optimize R&D and spark innovation. There are several reasons why. Aggressive goals that underpin potential major innovations frequently look "impossible" at project outset, and therefore don't fit neatly into the typical stage-gate review process. The organization invariably shifts attention from the quality of projects to the quantity.

Even more seriously, there may be unintended shifts in what's driving innovation that elude any process of formal R&D management. The Exxon study revealed that a high percentage of commercialized innovations were motivated by "getting the ox out of the ditch" during hard times, not by proactive management of R&D--a mindset that yields more incremental improvements than blockbusters.

Innovation, when it comes, seems motivated by desperate acts to keep operations running, rather than by a creative environment that fosters ideas. R&D organizations soon focus more on surviving the next budget review than on inventing "the next big thing." While urgency often does spark creativity, tinder these circumstances, creativity is rarely applied to problems that will drive commercial breakthroughs.

Part of the problem is that the sheer number of projects intended to "balance" a portfolio may actually crowd out innovation. A paradoxical conclusion of the Exxon Chemical study was that fewer projects might have actually meant bolder discoveries. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Turn R&D Upside Down: When Product Development Pipelines Fail to Meet Aggressive Growth Targets, a Radical Transformation of R&D May Be Called For
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.